In June 2021, it merged its biotechnology business group and sold its shares in the former photonics business group in July 2022, officially transforming itself into a professional OEM of beauty and care products. However, the continued impact of China's embargo on factory operations, logistics and consumer demand, coupled with the impact of global inflation, has led to a decline in overall consumption in China, resulting in a negative impact on Kwong Lai's operations.

Looking ahead, Kuan Le pointed out that, in terms of the operation of the OEM industry in Shanghai, the construction of the new production line in Shanghai is expected to be completed and put into operation by the end of 2022, and through the expansion of production capacity and line optimisation, it is hoped that this will enable us to secure orders from major brands. （We expect the consumer market to pick up gradually with the lifting of the policy ban.

In addition, in the Taiwan business, we intend to diversify our operations into new areas such as health management and health care, as well as market development and the establishment of a health management platform.

In the future, Kwong Lai hopes to expand its diversified business in Taiwan and abroad through a multi-faceted business model to avoid over-concentration in a single market, thereby reducing the overall systemic risk of its operations, and hopes that after adjusting the direction of its operations, its overall operating results will gradually rebound and improve its overall operating conditions.